DiaMedica Therapeutics DMAC 深 滬
已收盤 10-24 16:00:00 美东时间
6.88
+0.120
+1.78%
華盛通- 最 高6.93
- 今 開6.91
- 成交量 30.95万股
- 最 低 6.70
- 昨 收 6.76
- 總市值 3.56亿
- 52周最高 7.4899
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 3.19
- 委 比 88.90%
- 總股本 5168.89万
- 歷史最高 10.88
- 量 比 1.10
- 振 幅 3.40%
- 歷史最低 1.12
- 每 手 1
- 風險率 1.12%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Gainers Genprex (NASDAQ:GNPX) stock increased by 88.1% to $0.47 during Wednesd...
10-15 20:09
DiaMedica Therapeutics Advances with Positive Trials and Funding
Diamedica Therapeutics ( ($DMAC) ) has released its Q2 earnings. Here is a brea...
08-14 12:24
DiaMedica Therapeutics Q2 EPS $(0.18) Beats $(0.19) Estimate
DiaMedica Therapeutics (NASDAQ:DMAC) reported quarterly losses of $(0.18) per share which beat the analyst consensus estimate of $(0.19) by 5.26 percent. This is a 38.46 percent decrease over losses of $(0.13) per share
08-13 04:15
Earnings Scheduled For August 12, 2025
Companies Reporting Before The Bell • Smithfield Foods (NASDAQ:SFD) is expected...
08-12 16:32
Exploring DiaMedica Therapeutics's Earnings Expectations
DiaMedica Therapeutics (NASDAQ:DMAC) is set to give its latest quarterly earnin...
08-12 03:02
DiaMedica Therapeutics appoints Julie Krop as Chief Medical Officer
DiaMedica Therapeutics (NASDAQ:DMAC) announced on Wednesday the appointment of Julie Krop as Chief Medical Officer (CMO), effective immediately. Krop will succeed Lorianne Masuoka, who has resigned ...
08-06 20:48
DiaMedica Announces $30.1M Private Placement for DM199
Diamedica Therapeutics ( ($DMAC) ) has shared an announcement. On July 21, 2025...
07-21 20:56
DiaMedica Therapeutics raises $30 million in private placement
DiaMedica Therapeutics (NASDAQ:DMAC) announced on Monday definitive agreements for a $30.1 million private placement of common shares led by current investors. Pursuant to the terms of the securities ...
07-21 20:27
美股大行评级 | 潜在涨幅163.16%！Craig-Hallum上调DiaMedica Therapeutics目标价至11美元，维持"买入"评级
今日重点评级关注：Craig-Hallum：维持DiaMedica Therapeutics"买入"评级，目标价从8美元升至11美元；花旗：维持Cogent Biosciences"买入"评级，目标价从15美元升至22美元
07-21 09:19
